Glucagon (19-29), human
(Synonyms: H2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH ) 目录号 : GP10122
Glucagon (19-29), human 是一种有效的胰岛素分泌抑制剂。
Cas No.:64790-15-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Glucagon(NH2-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-COOH) is a peptide hormone, secreted by the pancreas, that raises blood glucose levels. Glucagon’s effect is opposite that of insulin, which lowers blood glucose levels. Miniglucagon (Glucagon 19–29) is a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ Pathway*. Miniglucagon is a novel local regulator of the pancreatic islet physiology. Any abnormal inhibitory tone exerted by this peptide on the β-cell results in impaired insulin secretion, as observed in type 2 diabetes. Miniglucagon is a component of the positive inotropic effect of glucagon. Some evidence has shown that glucagon processing into miniglucagon may be essential for the positive inotropic effect of glucagon on heart contraction.
References:
1. Reece J, Campbell N (2002). Biology. San Francisco: Benjamin Cummings. ISBN 0-8053-6624-5.
2. Stéphane Dalle, Ghislaine Fontés, Anne-Dominique Lajoix2, Laurence LeBrigand, René Gross, Gérard Ribes, Michel Dufour, Léo Barry, Dung LeNguyen and Dominique Bataille, Miniglucagon (Glucagon 19-29) A Novel Regulator of the Pancreatic Islet Physiology, doi:10.2337/diabetes.51.2.406Diabetes February 2002 vol. 51 no. 2406-412
3. Pavoine C, Brechler V, Kervan A, Blache Kervan, Le-Nguyen D, Laurent S, Bataille D, Pecker F (1991) Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol 260:C993–C999.
Animal experiment: | Rats[1]To test the effect of miniglucagon (Glucagon (19-29)) on stimulated insulin secretion, 8.3 mM glucose is perfused during the experiments, including a 45-min equilibration period, followed by miniglucagon (1, 10, 100, and 1,000 pM) perfused with or without 1 nM tGLP-1. To study the glucagon and miniglucagon secretion, the glucose concentration is switched from 11 to 3 mM after a 45-min stabilization period, and the peptides secreted are measured by radioimmunoassay[1]. |
References: [1]. Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76. | |
| Cas No. | 64790-15-4 | SDF | |
| 别名 | H2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH | ||
| 化学名 | Glucagon (19-29), human | ||
| Canonical SMILES | CC(C)CC(C(=O)NC(CCSC)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)C(C)N | ||
| 分子式 | C61H89N15O18S | 分子量 | 1352.51 |
| 溶解度 | ≥ 135.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7394 mL | 3.6968 mL | 7.3937 mL |
| 5 mM | 0.1479 mL | 0.7394 mL | 1.4787 mL |
| 10 mM | 0.0739 mL | 0.3697 mL | 0.7394 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet